Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 451

1.

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.

Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H.

J Clin Oncol. 2019 Dec 18:JCO1901406. doi: 10.1200/JCO.19.01406. [Epub ahead of print]

PMID:
31851556
2.

Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial.

Papakonstantinou A, Matikas A, Bengtsson NO, Malmström P, Hedayati E, Steger G, Untch M, Hübbert L, Johansson H, Hellström M, Gnant M, Loibl S, Greil R, Moebus V, Foukakis T, Bergh J.

Cancer. 2019 Dec 18. doi: 10.1002/cncr.32653. [Epub ahead of print]

PMID:
31851385
3.

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.

Wagner SM, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P, Simonitsch-Klupp I, Panny M, Lehner B, Greil R, Keil F, Jäger U, Sillaber C.

Eur J Haematol. 2019 Dec 15. doi: 10.1111/ejh.13368. [Epub ahead of print]

PMID:
31838747
4.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP.

N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914609. [Epub ahead of print] Erratum in: N Engl J Med. 2019 Dec 27;:.

PMID:
31825569
5.

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients.

Schlick K, Magnes T, Huemer F, Ratzinger L, Weiss L, Pichler M, Melchardt T, Greil R, Egle A.

J Clin Med. 2019 Oct 25;8(11). pii: E1791. doi: 10.3390/jcm8111791.

6.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B.

Br J Haematol. 2019 Nov 8. doi: 10.1111/bjh.16300. [Epub ahead of print]

PMID:
31702836
7.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators.

Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.

PMID:
31679945
8.

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.

Lang D, Huemer F, Rinnerthaler G, Horner A, Wass R, Brehm E, Akbari K, Granitz M, Hutarew G, Kaiser B, Greil R, Lamprecht B.

Target Oncol. 2019 Dec;14(6):707-717. doi: 10.1007/s11523-019-00679-9.

9.

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.

Willenbacher E, Jöhrer K, Willenbacher W, Flögel B, Greil R, Kircher B.

Ann Hematol. 2019 Nov;98(11):2569-2578. doi: 10.1007/s00277-019-03797-6. Epub 2019 Oct 18. Review.

10.

Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.

Seeber A, Weiss L, Romeder F, Szkandera J, Kuehr T, Kostner S, Pichler P, Jaeger T, Kocher F, Greil R, Brodowicz T.

Wien Klin Wochenschr. 2019 Oct 16. doi: 10.1007/s00508-019-01556-1. [Epub ahead of print]

PMID:
31620878
11.

Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.

Papakonstantinou A, Hedayati E, Hellström M, Johansson H, Gnant M, Steger G, Greil R, Untch M, Moebus V, Loibl S, Foukakis T, Bergh J, Matikas A.

Acta Oncol. 2020 Jan;59(1):75-81. doi: 10.1080/0284186X.2019.1670353. Epub 2019 Oct 4.

PMID:
31583943
12.

Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.

Scheithauer W, Putora PM, Grünberger B, Eisterer W, Wöll E, Prager G, Schaberl-Moser R, Greil R, Glatzer M.

Therap Adv Gastroenterol. 2019 Sep 23;12:1756284819877635. doi: 10.1177/1756284819877635. eCollection 2019. Erratum in: Therap Adv Gastroenterol. 2019 Dec 5;12:1756284819895730.

13.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N.

Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.

14.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N.

Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1666381. [Epub ahead of print]

PMID:
31556753
15.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.

Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.

PMID:
31554635
16.

B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion.

Asslaber D, Qi Y, Maeding N, Steiner M, Denk U, Höpner JP, Hartmann TN, Zaborsky N, Greil R, Egle A.

Blood. 2019 Nov 14;134(20):1717-1729. doi: 10.1182/blood.2019000973.

17.

Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy.

Wöll E, Eisterer W, Gerger A, Kühr T, Prager GW, Rumpold H, Ulrich-Pur H, Vogl U, Winder T, Weiss L, Greil R.

Anticancer Res. 2019 Sep;39(9):4589-4596. doi: 10.21873/anticanres.13638. Review.

PMID:
31519555
18.

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A.

J Clin Oncol. 2019 Nov 1;37(31):2835-2845. doi: 10.1200/JCO.19.00964. Epub 2019 Sep 10.

PMID:
31498753
19.

Mouse models to decipher anti-tumor immunity.

Parigger T, Greil R, Zaborsky N.

Oncotarget. 2019 Aug 20;10(49):5005-5006. doi: 10.18632/oncotarget.27111. eCollection 2019 Aug 20. No abstract available.

20.

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG.

Haematologica. 2019 Aug 14. pii: haematol.2019.223743. doi: 10.3324/haematol.2019.223743. [Epub ahead of print]

21.

Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis.

Haslbauer F, Petzer A, Safanda M, Tomova A, Porubska M, Bajory Z, Niepel D, Jaeger C, Bjorklof K, Kalinin D, Greil R.

Support Care Cancer. 2019 Jul 26. doi: 10.1007/s00520-019-04988-7. [Epub ahead of print]

PMID:
31350601
22.

Transcatheter aortic valve implantation in a patient with suspected hereditary von Willebrand disease and severe gastrointestinal bleeding - a case report.

Mirna M, Lichtenauer M, Theurl T, Ausserwinkler M, Topf A, Westphal T, Gampenrieder SP, Pretsch I, Greil R, Hoppe UC.

Scott Med J. 2019 Nov;64(4):142-147. doi: 10.1177/0036933019862155. Epub 2019 Jul 19.

PMID:
31324129
23.

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.

Huemer F, Lang D, Westphal T, Gampenrieder SP, Hutarew G, Weiss L, Hackl H, Lamprecht B, Rinnerthaler G, Greil R.

J Clin Med. 2019 Jul 10;8(7). pii: E1014. doi: 10.3390/jcm8071014.

24.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25.

25.

Lignans and sesquiterpene lactones from Hypochaeris radicata subsp. neapolitana (Asteraceae, Cichorieae).

Shulha O, Çiçek SS, Wangensteen H, Kroes J, Mäder M, Girreser U, Sendker J, Jöhrer K, Greil R, Schühly W, Mangoni A, Grauso L, van Thriel C, Zidorn C.

Phytochemistry. 2019 Sep;165:112047. doi: 10.1016/j.phytochem.2019.05.020. Epub 2019 Jun 13.

PMID:
31203102
26.

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

Singer CF, Filipits M, Jahn SW, Abete L, Jakesz R, Greil R, Bauernhofer T, Kwasny W, Seifert M, Fitzal F, Kastner M, Schmitt M, Moinfar F, Gnant M.

Breast. 2019 Aug;46:101-107. doi: 10.1016/j.breast.2019.05.007. Epub 2019 May 3.

PMID:
31132475
27.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2019 Jun;269(6):1163-1169. doi: 10.1097/SLA.0000000000002771.

PMID:
31082916
28.

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M.

Clin Cancer Res. 2019 Jul 1;25(13):3865-3872. doi: 10.1158/1078-0432.CCR-19-0376. Epub 2019 May 7.

PMID:
31064782
29.

Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.

Huemer F, Schlintl V, Hecht S, Hackl H, Melchardt T, Rinnerthaler G, Greil R, Weiss L.

Clin Colorectal Cancer. 2019 Jun;18(2):159-166.e3. doi: 10.1016/j.clcc.2019.04.003. Epub 2019 Apr 11.

30.

Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination.

Rivera FJ, de la Fuente AG, Zhao C, Silva ME, Gonzalez GA, Wodnar R, Feichtner M, Lange S, Errea O, Priglinger E, O'Sullivan A, Romanelli P, Jadasz JJ, Brachtl G, Greil R, Tempfer H, Traweger A, Bátiz LF, Küry P, Couillard-Despres S, Franklin RJM, Aigner L.

Glia. 2019 Aug;67(8):1510-1525. doi: 10.1002/glia.23624. Epub 2019 Apr 30.

31.

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Egle A, Melchardt T, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Voskova D, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Weiss L, Magnes T, Pleyer L, Klingler A, Mayer J, Greil R.

Cancer Med. 2019 Apr;8(4):1401-1405. doi: 10.1002/cam4.1980. Epub 2019 Mar 19.

32.

Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells.

Bolger GT, Licollari A, Bagshaw R, Tan A, Greil R, Vcelar B, Majeed M, Sordillo P.

Anticancer Res. 2019 Mar;39(3):1161-1168. doi: 10.21873/anticanres.13225.

PMID:
30842145
33.

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.

Rinnerthaler G, Gampenrieder SP, Greil R.

Int J Mol Sci. 2019 Mar 5;20(5). pii: E1115. doi: 10.3390/ijms20051115. Review.

34.

Cytotoxic Properties of Damiana (Turnera diffusa) Extracts and Constituents and A Validated Quantitative UHPLC-DAD Assay.

Willer J, Jöhrer K, Greil R, Zidorn C, Çiçek SS.

Molecules. 2019 Feb 28;24(5). pii: E855. doi: 10.3390/molecules24050855.

35.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
36.

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L.

Cancers (Basel). 2019 Feb 21;11(2). pii: E252. doi: 10.3390/cancers11020252. Review.

37.

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Huemer F, Melchardt T, Jansko B, Wahida A, Jilg S, Jost PJ, Klieser E, Steiger K, Magnes T, Pleyer L, Greil-Ressler S, Rass C, Greil R, Egle A.

Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.

38.

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, Westphal T, Riedmann M, Meissnitzer T, Egger H, Klaassen Federspiel F, Reitsamer R, Hauser-Kronberger C, Stering K, Hergan K, Mlineritsch B, Greil R.

Breast Cancer Res. 2019 Jan 31;21(1):19. doi: 10.1186/s13058-018-1091-y.

39.

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics.

Huemer F, Rinnerthaler G, Lang D, Hackl H, Lamprecht B, Greil R.

Ann Oncol. 2019 Apr 1;30(4):652-653. doi: 10.1093/annonc/mdz021. No abstract available.

40.

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle A.

Pharmacogenomics J. 2019 Jan 18. doi: 10.1038/s41397-019-0073-5. [Epub ahead of print]

PMID:
30659276
41.

ASCO 2018 highlights: metastatic breast cancer.

Rinnerthaler G, Gampenrieder SP, Greil R.

Memo. 2018;11(4):276-279. doi: 10.1007/s12254-018-0450-9. Epub 2018 Nov 20. Review.

42.

Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia.

Schubert M, Hackl H, Gassner FJ, Greil R, Geisberger R.

PLoS One. 2018 Dec 20;13(12):e0208753. doi: 10.1371/journal.pone.0208753. eCollection 2018.

43.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group.

Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.

PMID:
30563875
44.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW.

Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30522969
45.

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Asslaber D, Wacht N, Leisch M, Qi Y, Maeding N, Hufnagl C, Jansko B, Zaborsky N, Villunger A, Hartmann TN, Greil R, Egle A.

Clin Cancer Res. 2019 Mar 15;25(6):1901-1912. doi: 10.1158/1078-0432.CCR-18-1548. Epub 2018 Nov 28.

PMID:
30487125
46.

Risks and chances of aberrant DNA repair in cancer.

Schubert M, Greil R, Geisberger R.

Oncoscience. 2018 Aug 22;5(9-10):256-257. doi: 10.18632/oncoscience.459. eCollection 2018 Sep. No abstract available.

47.

Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.

Bolger GT, Licollari A, Tan A, Greil R, Vcelar B, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B, Majeed M, Sordillo PP.

Cancer Chemother Pharmacol. 2019 Feb;83(2):265-275. doi: 10.1007/s00280-018-3730-5. Epub 2018 Nov 14.

PMID:
30430227
48.

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.

Westphal T, Rinnerthaler G, Gampenrieder SP, Niebauer J, Thaler J, Pfob M, Fuchs D, Riedmann M, Mayr B, Reich B, Melchardt T, Mlineritsch B, Pleyer L, Greil R.

Cancer Med. 2018 Dec;7(12):5962-5972. doi: 10.1002/cam4.1851. Epub 2018 Nov 10.

49.

Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.

Schlick K, Magnes T, Ratzinger L, Jaud B, Weiss L, Melchardt T, Greil R, Egle A.

PLoS One. 2018 Nov 9;13(11):e0206688. doi: 10.1371/journal.pone.0206688. eCollection 2018.

50.

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R.

BMC Cancer. 2018 Nov 6;18(1):1074. doi: 10.1186/s12885-018-4979-0.

Supplemental Content

Support Center